We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00430352
First Posted: February 1, 2007
Last Update Posted: August 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hoffmann-La Roche
  Purpose
This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy following a MabThera-containing induction regimen in first line or relapsed patients with follicular non-Hodgkin's lymphoma. All patients will receive MabThera 375mg/m2 body surface area, as an intravenous infusion, every 8 weeks. The anticipated time on study treatment is 1-2 years, and the target sample size is 500+ individuals.

Condition Intervention Phase
Non-Hodgkin's Lymphoma Drug: rituximab [MabThera/Rituxan] Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy.

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of Participants With an Adverse Event (AE) - Overall Summary [ Time Frame: 24 months ]
    Data presented include percentage of participants with any AE, any infusion-related AE, any serious adverse event (SAE), any infusion-related SAE (counted separately from SAEs), death, and participants with toxicity as the primary cause for treatment discontinuation.


Secondary Outcome Measures:
  • Progression-Free Survival - Percentage of Participants With an Event [ Time Frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose ]
    PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.

  • Progression-Free Survival - Time to Event [ Time Frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose ]
    PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.

  • Event-Free Survival (EFS) - Percentage of Participants With an Event [ Time Frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose ]
    The percentage of participants who experienced PD or death or required a next or new lymphoma treatment over a study period of 2 years with 1 year of follow-up. EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.

  • Event-Free Survival (EFS) - Time to Event [ Time Frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose ]
    EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.

  • Overall Survival (OS) - Percentage of Participants With an Event [ Time Frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose ]
    As a measure of overall survival (OS), the percentage of participants who died over the study period of 2 years with 1 year of follow-up. OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.

  • Overall Survival (OS) - Time to Event [ Time Frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose ]
    OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.

  • Time to Next Lymphoma Treatment (NLT) - Percentage of Participants With an Event [ Time Frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose ]
    As a measure of time to NLT (TNLT), the percentage of participants with new lymphoma treatment over a study period of 2 years with 1 year of follow-up. TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.

  • Time to NLT - Time to Event [ Time Frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose ]
    TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.

  • Percentage of Participants With Response by Best Response to Study Treatment [ Time Frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose ]
    Percentage of participants with complete response (CR), unconfirmed CR (CRu), no change, or progressive disease (PD). For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Where possible, assessment of response was based on the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma (NHL).

  • Percentage of Participants With PR Who Converted to CRu [ Time Frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose ]
    Percentage of participants with PR or CR(u) conversion while on rituximab maintenance therapy over a study period of 2 years with 1 year of follow-up. For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Assessment and definition of response was based on the International Workshop to Standardize Response Criteria for NHL.


Enrollment: 545
Actual Study Start Date: September 4, 2006
Study Completion Date: May 26, 2011
Primary Completion Date: May 26, 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: rituximab [MabThera/Rituxan]
375mg/m2 iv every 8 weeks

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • histologically confirmed grade 1, 2 or 3a follicular non-Hodgkin's lymphoma;
  • patients who have received adequate (>=8 cycles) induction therapy with MabThera as first line treatment, or treatment for relapsed disease;
  • demonstrated partial or complete response to induction therapy.

Exclusion Criteria:

  • stable or progressive disease after most recent induction therapy;
  • transformation to high grade lymphoma;
  • patients with prior or concomitant malignancies, except non-melanoma skin cancer or adequately treated in situ cancer of the cervix.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00430352


  Hide Study Locations
Locations
Albania
University "Mother Theresa" Hospital Center; Oncology Department
Tirana, Albania, 1000
Argentina
Instituo Lavalle de Oncologia; Hematology
Bahia Blanca, Argentina, 8001
Academia Nacional de Medicina; Inst. de Cardiologia
Buenos Aires, Argentina, 1425
Fundaleu; Haematology
Buenos Aires, Argentina, C1114AAN
Hospital Churruca Visca; Haematology
Buenos Aires, Argentina, C1437JCP
Hospital Jr Vidal; Jefe de Servicio de Clinica Medica/Hematologia
Corrientes, Argentina, 3400
Sanatorio Allende; Haematology
Córdoba, Argentina, 5000
HOSPITAL PRIVADO - CENTRO MEDICO DE CÓRDOBA; Dpto Oncología
Córdoba, Argentina, 5016
Hospital General San Martin; Haematology
La Plata, Argentina, B1904CFS
Australia, New South Wales
Liverpool Hospital; Haematology
Liverpool, New South Wales, Australia, 2170
Wollongong Hospital; Cancer Services
Wollongong, New South Wales, Australia, 2500
Australia, Queensland
Royal Brisbane Hospital; Oncology Department
Brisbane, Queensland, Australia, 4006
Haematology & Oncology Clinics of Australia, Mater Medical Centre
South Brisbane, Queensland, Australia, 4101
Australia, Western Australia
Mount Medical Center
Perth, Western Australia, Australia, 6000
Bosnia and Herzegovina
University Clinical Center of the Republic of Srpska, Clinic for Internal Disease, Hematology Dept
Banja Luka, Bosnia and Herzegovina, 88000
Inst. of Hematology
Kasindo, Bosnia and Herzegovina, 71123
Uni Hospital Mostar
Mostar, Bosnia and Herzegovina, 88000
Clinic of Oncology, University Clinical Center Sarajevo
Sarajevo, Bosnia and Herzegovina, 71000
Brazil
Nucleo de Oncologia da Bahia - NOB
Salvador, Bahia, BA, Brazil, 40170-380
CEHON
Salvador, BA, Brazil, 40110-150
ONCOMED
Belo Horizonte, MG, Brazil, 30140-083
Centro de Tratamento Oncologico - Oncoclinica
Rio de Janeiro, RJ, Brazil, 22640-000
Hospital das Clinicas - UFRGS; Medicina Interna
Porto Alegre, RS, Brazil, 90035-903
Hospital Mae de Deus
Porto Alegre, RS, Brazil, 90470-340
Hospital Sao Lucas - PUCRS
Porto Alegre, RS, Brazil, 90610-000
Centro de Pesquisas Oncologicas - CEPON
Florianopolis, SC, Brazil, 88034-000
Hospital das Clinicas - UNICAMP; Hemoterapia
Campinas, SP, Brazil, 13083-878
Clinica Oncologica De Piracicaba Sc
Piracicaba, SP, Brazil, 13419-155
Hospital Alemao Oswaldo Cruz; Oncologia
Sao Paulo, SP, Brazil, 01323-020
Hospital Estadual do Servidor Publico; Hematologia
Sao Paulo, SP, Brazil, 04029-000
Hospital das Clinicas - FMUSP, Oncologia
Sao Paulo, SP, Brazil, 05403-000
Bulgaria
UMHAT Dr Georgi Stranski; Hematology
Pleven, Bulgaria, 5800
Umhat S. George; Hematology
Plovdiv, Bulgaria, 4002
UMHAT Alexandrovska EAD; Hematology
Sofia, Bulgaria, 1431
National Center of Hematology & Transfusiology; Clinical Unit, Clinic of Hematology
Sofia, Bulgaria, 1757
Mhat Sveta Marina; Dept. of Haematology
Varna, Bulgaria, 9010
Colombia
Centro Médico Carlos Ardila Lule
Bucaramanga, Colombia
Hospital Pablo Tobon Uribe
Medellin-Antioquia, Colombia
Croatia
Clinical Hospital Centre Split; Dept Of Hematology
Split, Croatia, 21000
Clinical Hospital Centre Dubrava; Hematology Department
Zagreb, Croatia, 10000
University Hospital Center Zagreb; Haematology Department
Zagreb, Croatia, 10000
Ecuador
Hospital José Carrasco; Oncology Service
Cuenca, Ecuador
Hospital Carlos Andrade Marin; Servicio de Oncología
Quito, Ecuador, 2569
Egypt
Oncology & Radiotherapy Centre; Oncology
Cairo, Egypt, 11737
Finland
Kanta-Hämeen Keskussairaala; Dept of Internal Medicine, Hematology
Haemeenlinna, Finland, 13530
Kymenlaakson keskussairaala
Kotka, Finland, 48210
Päijät-Hämeen Keskussairaala; Dept of Internal Medicine, Hematology
Lahti, Finland, 15850
Satakunnan Keskussairaala; Sisaetauti Osasto
Pori, Finland, 28500
Germany
Internist; Praxis Für Haemotologie & Onkologie
Bad Soden, Germany, 65812
Dres.Christian Sperling und Claudia Schelenz
Berlin, Germany, 10117
Onkologische Schwerpunktpraxis Kurfürstendamm
Berlin, Germany, 10707
Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin
Bonn, Germany, 53127
Dres. Matthias Adler Oliver Marschal und Andreas Pies
Braunschweig, Germany, 38100
Gemeinschaftspraxis
Duisburg, Germany, 47051
Internistische Praxis Dr. Plingen
Düsseldorf, Germany, 40211
Internistische Schwerpunktpraxis Erlangen
Erlangen, Germany, 91052
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
Freiburg, Germany, 79110
Onkologische Gemeinschaftspraxis, Prof. Dr. Gropp, Dr. Depenbusch und Dr. Rösel
Gütersloh, Germany, 33332
Überörtliche Gemeinschaftspraxis Schwerpunkt Hämatologie, internistische Onkologie & Palliativmed.
Hamburg, Germany, 20259
Onkologische Schwerpunktpraxis; Herrn Dr. Med. Bertram
Hamburg, Germany, 22457
Dres.Andreas Karcher und Stefan Fuxius
Heidelberg, Germany, 69115
Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V
Heidelberg, Germany, 69120
Onkologische Schwerpunktpraxis (Eps-Gmbh)
Jena, Germany, 07743
Märkische Kliniken GmbH, Klinikum Lüdenscheid; Hämatologie / Onkologie
Lüdenscheid, Germany, 58515
Stauferklinikum Schwäb.Gmünd
Mutlangen, Germany, 73557
Gemeinschaftspraxis Dres. Schröder, Sieg
Mülheim, Germany, 45468
Onko. Gemeinschaftspraxis Dres. Tigges/ Böning/ Abenhardt/ Bosse
München, Germany, 80335
Dres.Ulrich Hutzschenreuter und Uwe Sauer
Nordhorn, Germany, 48527
Onkologische Praxis Oldenburg; Dres. Otremba, Reschke, Zirpel, Kühn und Ruff
Oldenburg, Germany, 26121
Praxis für Onkologie und Hämatologie
Recklinghausen, Germany, 45657
Diakonie-Klinikum Klinik für Innere Medizin III Abt.Hämatologie, intern. Onkologie und Palliativmedi
Schwäbisch-Hall, Germany, 74523
Internistische Gemeinschaftspraxis Dres. Hoering/Von Ehr/Responde
Stuttgart, Germany, 70176
Haematologisch-Onkologische Praxis; Dr. med. Christoph Maintz und Matthias Groschek
Wuerselen, Germany, 52146
Greece
Laiko General Hospital - Uni of Athens; 1St Dept. of Internal Medicine
Athens, Greece, 11524
Attiko Hospital; Haematology Clinic
Athens, Greece, 124 62
Theagenio Anticancer Hospital; Dept. of Haematology
Thessaloniki, Greece, 54007
Israel
Rambam Medical Center; Heamatology & Bone Marrow Transplantation
Haifa, Israel, 3109601
Wolfson Mc; Haematology
Holon, Israel, 5810001
Hadassah Ein Karem Hospital; Haematology
Jerusalem, Israel, 9112001
Chaim Sheba Medical Center; Hematology BMT & CBB
Ramat Gan, Israel, 52662
Ichilov Sourasky Medical Center; Heamatology
Tel Aviv, Israel, 6423906
Italy
Ospedale Civile Dello Spirito Santo; Divisione Di Ematologia
Pescara, Abruzzo, Italy, 65100
Az. Osp. Pugliese; Dh Oncologico
Catanzaro, Calabria, Italy, 88100
Ospedale S. Gennaro; Divisione Di Ematologia
Napoli, Campania, Italy, 80100
Ospedale Cardarelli; Divisione Di Ematologia
Napoli, Campania, Italy, 80131
A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
Bologna, Emilia-Romagna, Italy, 40138
Arcispedale S. Anna; Sezione Di Ematologia
Ferrara, Emilia-Romagna, Italy, 44100
A.O. Universitaria Policlinico Di Modena; Ematologia
Modena, Emilia-Romagna, Italy, 41100
A.O.U. Policlinico di Modena-Dipartimento di Medicina Diagnostica, Clinica e di Sanità pubblica
Modena, Emilia-Romagna, Italy, 41100
Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica
Aviano, Friuli-Venezia Giulia, Italy, 33081
Az. Osp. Uni Ria Policlinico Tor Vergata; Unita Di Ematologia
Roma, Lazio, Italy, 00133
Ospedale S. Eugenio; Divisione Di Ematologia
Roma, Lazio, Italy, 00144
Univ. Cattolica La Sapienza; Cattedra Di Ematologia
Roma, Lazio, Italy, 00161
Uni Cattolica; Divisione Di Ematologia
Roma, Lazio, Italy, 00168
A.O. Universitaria S. Martino Di Genova; Ematologia 1
Genova, Liguria, Italy, 16132
A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia
Brescia, Lombardia, Italy, 25123
Istituto S. Raffaele Monte Tabor; Divisione Ematologia E Utmo
Milano, Lombardia, Italy, 20132
Ist. Nazionale Per Lo Studio E Cura Dei Tumori; Div. Ematologia Trapianto Midollo Osseo Allogenico
Milano, Lombardia, Italy, 20133
Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
Milano, Lombardia, Italy, 20162
ASST DI MONZA; Ematologia
Monza, Lombardia, Italy, 20052
Irccs Policlinico San Matteo; Divisione Di Ematologia
Pavia, Lombardia, Italy, 27100
Ospedale Civile; S.C. Ematologia
Pesaro, Marche, Italy, 61100
A.O. Univ.Ospedali Riuniti Umerto I -G.M.Lancisi G.Salesi; U.O. Clinica Di Ematologia
Torrette Di Ancona, Marche, Italy, 60020
Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico
Candiolo, Piemonte, Italy, 10060
Az. Osp. S. Croce Ospedale Generale; Sezione Di Ematologia
Cuneo, Piemonte, Italy, 12100
Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.& Ircad
Novara, Piemonte, Italy, 28100
A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1
Torino, Piemonte, Italy, 10126
A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia
Torino, Piemonte, Italy, 10126
Uni Degli Studi Di Bari, Policlinico; Cattedra Di Ematologia,Dipart. Di Medicina Interna E Publica
Bari, Puglia, Italy, 70124
Ospedale Vito Fazzi; Div. Oncoematologia
Lecce, Puglia, Italy, 73100
Az. Osp. C. Panico; Rep. Ematologia E Trapianto
Tricase - Le, Puglia, Italy, 73039
Ospedale Oncologico A Businco-Cagliari; Ematologia Sez.
Cagliari, Sardegna, Italy, 09121
Ospedale V. Cervello; U.O. Ematologia E Trapianti
Palermo, Sicilia, Italy, 90146
Ospedale Ferrarotto; Divisione Di Ematologia
Via S. Sofia 78, Sicilia, Italy, 95123
Az. Osp. Di Careggi; Divisione Di Ematologia
Firenze, Toscana, Italy, 50135
Ospedale Santa Chiara; Unita Operativa Di Ematologia
Pisa, Toscana, Italy, 56100
A.O. Universitaria Senese; Ematologia
Siena, Toscana, Italy, 53100
Azienda Ospedaliera S. Maria della Misericordia; Ematologia
Perugia, Umbria, Italy, 06100
Uni Degli Studi; Dip.Med.Clinica E Sperim. Ematologia
Padova, Veneto, Italy, 35128
Ospedale Di Vicenza; Nefrologia, Ematologia
Vicenza, Veneto, Italy, 36100
Mexico
Issste; Haematology
Chihuahua, Mexico, 31100
Hospital Cima (Centro Internacional de Medicina) ; Haematology
Chihuahua, Mexico, 31238
Hospital Central de Pemex Norte Azcapotzalco
Mexico City, Mexico, 02720
Hospital Español de Mexico
Mexico City, Mexico, 11520
Hospital Regional Issste; Oncologia
Monterrey, Mexico, 64380
Clinca San Jose; Haematology
Obregon, Mexico, 85000
Issstep Puebla, ; Haematology
Puebla, Mexico, 72530
Romania
Spitalul Clinic Judetean de Urgenta Brasov,Clinica de Hematologie
Brasov, Romania, 500326
Fundeni Clinical Inst. ; Hematology Dept
Bucharest, Romania, 022328
Spitalul Clinic Coltea; Clinica de Hematologie
Bucuresti, Romania, 030171
Oncology Inst. Cluj-Napoca; Cancer Dept
Cluj-Napoca, Romania, 400015
Spitalul Clinic Judetean de Urgenta Sf. Spiridon Iasi, Clinica de Hematologie
Iasi, Romania, 700111
Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie
Targu-mures, Romania, 540136
Russian Federation
Regional Clinical Hospital; Hematology
Belgorod, Russian Federation, ND
Clinical Oncology Dispensary of Ministry of Health of Tatarstan
Kazan, Russian Federation, 420029
Blokhin Cancer Research Center; Clinical Oncology
Moscow, Russian Federation, 115478
City Clinical Hospital After Botkin; Hematology
Moscow, Russian Federation, 125101
Vladimirskiy Regional Scientific Research Inst. ; Hematology
Moscow, Russian Federation, 129110
Regional Clinical Hospital N.A. Semashko; Hematology
Nizhny Novgorod, Russian Federation, 603126
City Hematological Center of Clinical Hospital #2; Hematology
Novosibirsk, Russian Federation, 630051
Rostov State Medical Uni ; Hematology
Rostov-na-donu, Russian Federation, 344022
Research Inst. of Hematology & Blood Transfusion ; Hematology
St Petersburg, Russian Federation, 191024
Pavlov State Medical Uni ; Bone Marrow Transplantation Clinic
St Petersburg, Russian Federation, 197022
Leningrad Regional Clinical Hospital; Hematology #1
St Petersburg, Russian Federation
Stavropol Clinical Oncology Dispansary
Stavropol, Russian Federation, ND
Bashkirian Republican Clinical Oncology Dispensary
UFA, Russian Federation, 450054
Ulyanovsk Regional Oncology Dispensary; Chemotherapy
Ulyanovsk, Russian Federation, ND
Regional Oncology Center; Chemotherapy
Volgograd, Russian Federation, 400138
Regional Clinical Hospital; Hematology
Yaroslavl, Russian Federation, 150062
Slovakia
Fakultna Nemocnica Roosevelta; Dept. of Haematology
Banska Bystrica, Slovakia, 975 17
National Oncology Inst. ; Dept. of Haematology
Bratislava, Slovakia, 833 10
Uni Hospital; Clinic of Haematology
Kosice, Slovakia, 040 66
Uni Hospital ; Dept. of Haematol. & Transfusion Medicine
Martin, Slovakia, 036 59
Slovenia
Institute of Oncology Ljubljana
Ljubljana, Slovenia, 1000
Spain
Complejo Asistencial Universitario De Burgos; Servicio de Oncologia
Burgos, Spain, 09006
Hospital General de Castellon; Servicio de Hematologia
Castellon, Spain, 12004
Hospital Generla de Ciudad Real; Servicio de Oncologia
Ciudad Real, Spain, 13005
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia
Jaen, Spain, 23007
Hospital El Bierzo; Servicio de Oncologia
Leon, Spain, 24411
Hospital Costa del Sol; Servicio de Hematologia
Malaga, Spain, 29600
Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia
Murcia, Spain, 30120
Hospital Universitario Virgen Macarena; Servicio de Hematologia
Sevilla, Spain, 41009
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
Valencia, Spain, 46010
Sweden
Laenssjukhuset; Medicinkliniken/Hematologsektionen
Halmstad, Sweden, 30185
Sunderby Sjukhus; Medicinkliniken
Luleå, Sweden, S-971 80
Skånes Universitetssjukhus; Kliniska Forskningsenheten Onkologimottagning medicinsk behandling
Malmö, Sweden, 205 02
Länssjukhuset Sundsvall-Härnösand, Medicinkliniken
Sundsvall, Sweden, 85186
Uddevalla Sjukhus; Medicinkliniken
Uddevalla, Sweden, 45180
Akademiska sjukhuset, Onkologkliniken
Uppsala, Sweden, 75185
Switzerland
Andreas Klinik; Onko-Hämatologisches Zentrum Cham Zug
Cham, Switzerland, 6330
Kantonsspital Graubünden;Onkologie und Hämatologie
Chur, Switzerland, 7000
Clinica Santa Chiara; Oncologia / Ematologia
Locarno, Switzerland, 6601
UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
Zürich, Switzerland, 8091
Turkey
Ankara Numune Egitim Ve Arastirma Hastanesi; Hematoloji Klinigi
Ankara, Turkey, 06100
Hacettepe Uni Medical Faculty; Hematology
Ankara, Turkey, 06100
Gazi Uni Medical School; Hematology
Ankara, Turkey, 06500
Istanbul Uni Capa Hospital; Hematology
Istanbul, Turkey, 34390
Ege Uni Medical School; Hematology
Izmir, Turkey, 35100
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00430352     History of Changes
Other Study ID Numbers: MO19872
First Submitted: January 31, 2007
First Posted: February 1, 2007
Results First Submitted: September 4, 2014
Results First Posted: June 8, 2015
Last Update Posted: August 14, 2017
Last Verified: July 2017

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Rituximab
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents